Morbidity and Mortality Review Unit, King Saud University Medical City; Department of Public Health, Research Chair of Evidence-Based Healthcare and Knowledge Translation, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Department of Medicine, Faculty of Medicine, Tabuk University, Tabuk, Saudi Arabia.
Saudi J Kidney Dis Transpl. 2021 Mar-Apr;32(2):468-480. doi: 10.4103/1319-2442.335459.
According to the elevated infection mortality risks, the incidence of coronavirus disease 2019 (COVID-19) could be raised in rheumatoid arthritis patients with end-stage renal disease (ESRD). Our objectives are to describe the impact of COVID-19 infection on rheumatoid arthritis patients with end-stage renal disease and to identify the risk of in-hospital mortality, comorbid conditions. and the proper way to deal with this category. It was a retrospective analysis of COVID-19 patients in Saudi Arabia from March 1, 2020 to April 27, 2020 and from May 27, 2020 to August 20, 2020. Of 10,482 patients with COVID-19, 419 had ESRD. We assessed main (in-hospital death) outcomes and secondary (mechanical breathing and residence) outcomes. Patients with ESRD were aged and more comorbid disorders. Rheumatoid arthritis patients with ESRD were aged. ESRD rheumatoid arthritis patients have a higher hospital mortality risk relative to rheumatoid arthritis patients not getting complicated with ESRD (31.7% vs. 25.4%, chances 1.38, and 95% trust range 1.12-1.70). After population and comorbid conditions had changed, the rate of rise stayed the same (changed chances: 1.37, 1.09-1.73). In both the crude and modified study (1.62, 1.26-2.07; vs. 1.57, 1.22-2.02), chances for the period of stay of seven or more days have been higher inside a group than in the non-ESRD group. Old age, respiratory support, lymphopenia, and elevated blood urea nitrogen and low serum ferritin were the independent contributing factors for the in-hospital mortality of ESRD rheumatoid arthritis patients infected with severe acute respiratory syndrome coronavirus 2.
根据感染死亡率升高的情况，终末期肾病（ESRD）的类风湿关节炎患者的 2019 年冠状病毒病（COVID-19）发病率可能会上升。我们的目的是描述 COVID-19 感染对终末期肾病的类风湿关节炎患者的影响，并确定住院死亡率、合并症的风险以及处理此类疾病的正确方法。这是对 2020 年 3 月 1 日至 4 月 27 日和 2020 年 5 月 27 日至 8 月 20 日期间在沙特阿拉伯的 COVID-19 患者进行的回顾性分析。在 10482 例 COVID-19 患者中，有 419 例患有 ESRD。我们评估了主要（住院死亡）结局和次要（机械通气和住院）结局。患有 ESRD 的患者年龄较大且合并症较多。患有 ESRD 的类风湿关节炎患者年龄较大。与未合并 ESRD 的类风湿关节炎患者相比，ESRD 类风湿关节炎患者的住院死亡率风险更高（31.7%比 25.4%，几率 1.38，95%置信区间 1.12-1.70）。在改变了人群和合并症后，上升率保持不变（改变的几率：1.37，1.09-1.73）。在未调整和调整后的研究中（1.62，1.26-2.07；vs. 1.57，1.22-2.02），住院时间超过 7 天的几率在 ESRD 组中高于非 ESRD 组。高龄、呼吸支持、淋巴细胞减少、血尿素氮升高和血清铁蛋白降低是 ESRD 类风湿关节炎患者感染严重急性呼吸综合征冠状病毒 2 后住院死亡的独立危险因素。
